Archives of Clinical Infectious Diseases
Volume 18 · Issue 5 · e139989

OPEN PEER REVIEW

The Role of Sinopharm BIBP COVID-19 Vaccine Immunization in Systemic Lupus Erythematous Flare-up

Parisa Delkash, Amir Azimi, Niloufar Taherpour, Saeid Haji Aghajani

SUBMITTED	REVISED	ACCEPTED	DOI
14 Aug 2023	22 Nov 2023	3 Dec 2023	10.5812/archcid-139989

About this report

This open peer review (OPR) report shows the public comments made on this article during peer review, by the reviewers, the associate editor and the editor-in-chief, for every revision round, together with the authors' replies. Comments appear only with the consent of the people who wrote them. Reviewers who chose to sign their report are named; the others are shown as "Referee". Comments are edited for language only, and confidential remarks to the editors are not included.

More about open peer review: brieflands.com/knowledgebase/opr

Contents

1 Original submission Referee 1 2
2 Revision 1 3
Authors' reply to reviewers 4
Reviewer and editor comments 5

1 Original submission

1 comment · 5 Nov 2023

Referee 1 Reviewer

MAJOR REVISION 5 Nov 2023

Dear authors,
I appreciate the time and effort you put into this case report. The topic is novel, interesting, and within the journal's scope. In my opinion, your manuscript can be accepted for publication after major revision. Please address my comments:
Title and abstract
1-Based on the method description, I believe that your study design was not a historical cohort study. The data were retrospectively collected, but you did not consider two groups of people from the beginning and follow their outcomes over time, which is the most important aspect of a cohort study. Instead, it should be mentioned that you conducted a cross-sectional study. Please apply this comment throughout the text.
Method
2- Was data collection based on the census method or sampling? If it was based on sampling, please add how the sample size was estimated and which sampling method was used. If not, please mention that it was based on the census method.
Discussion
3-Please discuss the role of immunosuppressive drugs received by RA patients as confounding variables in the emergence of disease flare-ups.
Best regards

2

Revision 1

AUTHORS' RESPONSE TO REVIEWERS

Authors' reply to reviewers

The next pages contain the authors' point-by-point reply to the comments of this revision round, as submitted with the revised manuscript. It is published as the authors wrote it.

Dear Editor-in-Chief

We want to express our sincere appreciation for overseeing the review of our manuscript submitted. We also extend our warm thanks to the reviewers for their valuable and constructive feedback on our manuscript. We are genuinely thankful for the opportunity to revise our work based on their comments.

Enclosed within this message, you will find our comprehensive responses and explanations addressing each of the reviewers; comments in the provided table. Additionally, all modifications made to the manuscript have been clearly highlighted in yellow for your convenience.

Thank you for your time and consideration.

Reply to the reviewer's comments

Reviewer	Reviewer Comments	Author answers	Changes
1	1-Based on the method description I believe that your study design was not historical cohort. The data were retrospectively collected, but from the beginning you did not consider two groups of the people and followed the outcomes during the time, which is the most issue in the cohort study. Instead, it should be mentioned that you conducted a cross-sectional study. Please apply this comment throughout the text.	Thanks for your nice comment. We have edited this statement in yellow highlight.	Page 1,2,5
	Was data collection based on census method or sampling? If it was based on sampling, please add how to estimate sample size and sampling method. If not, please mention it was based on the census method.	We have edited this statement in yellow highlight.	Page 2
	Please discuss about the role of immunosuppressive drugs, which are received by the RA patients, as confounding variables in the emergence of disease flare-up	We have edited this statement in yellow highlight.	Page 6

2 Revision 1

0 comments

No public comments in this round.